Life sciences briefing: Tuesday, Dec. 18, 2007
TODAY’S HEADLINES:
Elixir Pharma sets IPO range, seeks up to $92M for anti-aging drugs (Edgar)
Deltanoid Pharma raises $12M for kidney drugs (PDF release)
CovX, cancer and diabetes-drug biotech, acquired by Pfizer (release)
Affymetrix pays $75M for reagent maker USB (release)
Merrion Pharma postpones U.S. IPO, raises €5.6M in Dublin offering (Irish Independent)
Isis spinout Altair raising first round for asthma drugs (release)
“Human hydration” sensor maker Cantimer names Robin Stracey CEO (release)
Sensimed raises CHF 8M for glaucoma diagnostics (PE Hub)
Deltanoid Pharma… Continue Reading
Life sciences briefing: Wednesday, Sept. 12, 2007
Featured companies: Mawell, OpGen, Vital Therapeutics
Optical genome-mapper OpGen raises $23.6M in a restart — OpGen, a Madison, Wisc., biotech developing a genomic test for identifying disease-causing microbes, raised $23.6 million in what the company is billing as a first funding round. In fact, however, the funding is more of a restart for the company, which was founded in 2001 and previously provided genomic services to researchers.
OpGen is now focused on developing speedy genome-based tests that can… Continue Reading